Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

NCT03023319 is registered in ClinicalTrials.gov with Nagla Abdel Karim as lead sponsor.

NCT NCT03023319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03023319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Lead sponsor
Nagla Abdel Karim
Phase
Phase 1
Overall status
Completed
Start date
December 10, 2019
Completion date
May 10, 2022
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, carcinoma, non-small-cell lung, mesothelioma, ovarian cancer, peritoneal cancer, thymoma, thymus cancer, uterine cervical cancer